m-Tolylsulfat | 68127-34-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机硫酸及其衍生物
• 英文名称: m-Tolylsulfat
• 英文别名: sulfuric acid mono-m-tolyl ester；Schwefelsaeure-mono-m-tolylester；m-Tolyl-hydrogensulfat；Mono-m-tolylsulfat；m-Kresylschwefelsaeure；3-sulfonyloxy-toluene；m-Tolylschwefelsaeure；3-Methylphenyl hydrogen sulfate；(3-methylphenyl) hydrogen sulfate
• CAS: 68127-34-4
• 化学式: C₇H₈O₄S
• 分子量: 188.204
• InChiKey: HZGJZZQVDDYIIO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  72
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  m-Tolylsulfat 在 alkaline permanganate 作用下， 生成 间羟基苯甲酸
  参考文献：
  名称：

  Haworth; Lapworth, Journal of the Chemical Society, 1924, vol. 125, p. 1304

  摘要：

  DOI：
• 作为产物：
  描述：

  间甲酚 在 吡啶 、 二硫化碳 、 氯磺酸 作用下， 生成 m-Tolylsulfat
  参考文献：
  名称：

  Haworth; Lapworth, Journal of the Chemical Society, 1924, vol. 125, p. 1304

  摘要：

  DOI：

文献信息

• [EN] MAPK INHIBITORS<br/>[FR] INHIBITEURS DE MAPK
  申请人：WANG BING HUI

  公开号：WO2016029263A1

  公开（公告）日：2016-03-03

  The present invention relates to certain novel substituted thiophene compounds and the finding that they display useful efficacy in the inhibition of the p38α MAPK enzyme. This provides for use of the compounds in various treatment methodologies related to MAPK inhibition, including the treatment of inflammation.

  本发明涉及某些新颖的取代噻吩化合物，以及发现它们在抑制p38α MAPK酶方面显示出有用的功效。这使得这些化合物在与MAPK抑制相关的各种治疗方法中的使用成为可能，包括治疗炎症。
• Regional Accumulation of ¹⁴C-zonisamide in Rat Brain during Kainic Acid-induced Limbic Seizures
  作者：Koichi Akaike、Shigeya Tanaka、Hideshi Tojo、Shin-ichiro Fukumoto、Morikuni Takigawa、Shin-ichi Imamura

  DOI：10.1017/s0317167100001554

  日期：2001.11

  Zonisamide (ZNS) is an antiepileptic drug developed in Japan. Various experimental studies have investigated the effects of ZNS. However, the mechanism of action of ZNS against limbic seizures and secondary generalization is not well-known. We studied ictal regional accumulation of ZNS in the rat brain during kainic acid (KA)-induced limbic status epilepticus.

  Fourteen male Wistar rats underwent a stereotactic operation. For recording the electroencephalogram (EEG), electrodes were placed in the left amygdala (LA), left dorsal hippocampus, and over the left sensorimotor cortex. For microinjection, a stainless steel cannula was also inserted into the LA. Seven days after surgery, rats were anesthetized and a catheter was inserted into the femoral vein. The animals were immobilized and allowed to recover from anesthesia for at least two hours. In eight rats, 1.0μL (1.0μg) of KA was injected into the LA, and 1.0 μL of phosphate buffer solution was injected into the LA in six control rats. Sixty minutes after injection, ¹⁴C-ZNS was administered intravenously, and an autoradiographic study was done.

  During limbic status epilepticus, only seizures in the sensorimotor cortex were markedly attenuated a few minutes after ¹⁴C-ZNS administration. Additionally, high uptake of ¹⁴C-ZNS was noted ipsilaterally in the sensorimotor cortex, parietal cortex and thalamus (lateral portion). In control rats, no EEG change was seen, and distribution of ¹⁴C-ZNS was rather homogeneous.

  These results suggested that ZNS suppresses secondary generalization of limbic seizures by a direct effect on the cerebral cortex.

  背景：唑尼沙胺（ZNS）是日本开发的一种抗癫痫药物。各种实验研究都对 ZNS 的作用进行了调查。然而，ZNS对边缘型癫痫发作和继发性泛化的作用机制尚不清楚。方法：14 只雄性 Wistar 大鼠接受了立体定向手术。为了记录脑电图（EEG），电极被放置在左侧杏仁核（LA）、左侧海马背侧和左侧感觉运动皮层上。为了进行微量注射，还将不锈钢插管插入 LA。手术七天后，对大鼠进行麻醉，并将导管插入股静脉。将动物固定，让其从麻醉中恢复至少两小时。在 8 只大鼠的 LA 中注射 1.0μL （1.0μg）KA，在 6 只对照组大鼠的 LA 中注射 1.0μL 磷酸盐缓冲溶液。结果：在肢端状态癫痫期间，只有感觉运动皮层的癫痫发作在注射 14C-ZNS 几分钟后明显减弱。此外，在感觉运动皮层、顶叶皮层和丘脑（外侧部分）的同侧发现了对 14C-ZNS 的高摄取。结论：这些结果表明，ZNS 通过直接作用于大脑皮层来抑制肢体癫痫发作的继发性泛化。
• Synthesis of novel flavonoid derivatives as potential HIV- Integrase inhibitors
  作者：Nelly N. Mateeva、Rao N. Kode、Kinfe K. Redda

  DOI：10.1002/jhet.5570390620

  日期：2002.11

  Eighteen novel flavonoid derivatives - substituted chalcones and flavones were synthesized and characterized by using NMR, IR, UV/Vis spectroscopy and elemental analysis. The target compounds were achieved by using a sequence of simple and effective reactions starting from phloroglucinol. The initial hydroxyl groups were protected by methylation and in the final flavones the 5-OH group was selectively

  合成了十八种新的类黄酮衍生物-取代的查耳酮和黄酮，并通过NMR，IR，UV / Vis光谱和元素分析对其进行了表征。通过使用一系列从间苯三酚开始的简单有效的反应，可以实现目标化合物。最初的羟基被甲基化保护，而在最后的黄酮中，5-OH通过AlBr 3选择性地脱甲基。5-甲氧基黄酮显示强荧光，在除去甲基后将其猝灭。
• NOVEL COCRYSTALLIZATION
  申请人：CHILDS Scott L.

  公开号：US20090281195A1

  公开（公告）日：2009-11-12

  The present disclosure relates to novel cocrystals and novel methods for cocrystallization. In particular, the disclosure includes cocrystals comprising a salt of an active agent, such as a chloride salt of an active pharmaceutical ingredient. The present disclosure also relates to methods of preparing cocrystals and methods for screening for solid state phases.

  本公开涉及新型共晶体和新型共晶化方法。具体而言，公开包括由活性剂的盐组成的共晶体，例如活性药物成分的氯化物盐。本公开还涉及制备共晶体的方法和筛选固态相的方法。
• Biomarkers related to organ function
  申请人：University of Pittsburgh—Of the Commonwealth System of Higher Education

  公开号：US10634686B2

  公开（公告）日：2020-04-28

  Disclosed herein are methods of identifying biomarkers (such as genes (e.g., RNA or mRNA), proteins, and/or small molecules) that can be used to predict organ or tissue function or dysfunction. In some embodiments, the methods include ex vivo perfusion of the organ or tissue, collection of samples from the organ or tissue (for example, perfusate, fluids produced by the organ (such as bile or urine), or tissue biopsies) and measuring the level of one or more biomarkers in the sample. It is also disclosed herein that an analysis of biomarkers (such as genes (e.g., RNA or mRNA), proteins, and/or small molecules) present in a biological sample from an organ, tissue, or subject can be used to identify whether the organ, tissue, or subject is at risk for (or has) organ dysfunction or organ failure.

  本文公开了鉴定可用于预测器官或组织功能或功能障碍的生物标记物（如基因（如 RNA 或 mRNA）、蛋白质和/或小分子）的方法。在一些实施方案中，这些方法包括对器官或组织进行体外灌注，收集器官或组织的样本（例如灌注液、器官产生的液体（如胆汁或尿液）或组织活检），并测量样本中一种或多种生物标记物的水平。本文还公开了对来自器官、组织或受试者的生物样本中存在的生物标记物（如基因（如 RNA 或 mRNA）、蛋白质和/或小分子）的分析，可用于确定器官、组织或受试者是否有器官功能障碍或器官衰竭的风险（或已出现器官功能障碍或器官衰竭）。